Caribou Biosciences Reports Positive CRISPR Genome-Editing Results, Stock Surges 17.56% on Monday
ByAinvest
Monday, Nov 3, 2025 12:03 pm ET1min read
CRBU--
Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged 17.56% on Monday after the CRISPR genome-editing biopharmaceutical company shared preliminary results from its ongoing ANTLER phase 1 trial of vispacabtagene regedleucel, an allogeneic anti-CD19 CAR-T cell therapy, for relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy achieved a complete response in 64% of patients, with an overall response rate of 82% and a one-year progression-free survival rate of 51%. Caribou plans to conduct a randomized, controlled trial in second-line large B-cell lymphoma patients, and is advancing its CB-011 program for relapsed or refractory multiple myeloma.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet